Brown Advisory Inc. Grows Stock Position in Sanofi (NASDAQ:SNY)

Brown Advisory Inc. grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 31.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 314,636 shares of the company's stock after buying an additional 74,583 shares during the period. Brown Advisory Inc.'s holdings in Sanofi were worth $17,450,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Brighton Jones LLC grew its stake in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after purchasing an additional 1,869 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Sanofi by 8.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 151,945 shares of the company's stock worth $7,328,000 after purchasing an additional 12,440 shares during the period. Amundi grew its stake in Sanofi by 11.1% during the fourth quarter. Amundi now owns 630,063 shares of the company's stock worth $31,017,000 after purchasing an additional 63,195 shares during the period. Wealthfront Advisers LLC acquired a new stake in Sanofi during the fourth quarter worth approximately $1,908,000. Finally, HighTower Advisors LLC grew its stake in Sanofi by 3.4% during the fourth quarter. HighTower Advisors LLC now owns 91,071 shares of the company's stock worth $4,392,000 after purchasing an additional 2,971 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Barclays reissued an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. BNP Paribas assumed coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of "Buy" and a consensus price target of $61.50.

Sanofi Stock Down 1.5%

Shares of SNY stock traded down $0.73 during trading hours on Friday, reaching $48.61. The company had a trading volume of 1,207,445 shares, compared to its average volume of 2,330,352. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The business has a fifty day simple moving average of $50.05 and a 200-day simple moving average of $52.11. The company has a market cap of $119.21 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same quarter last year, the company earned $1.78 earnings per share. The company's revenue for the quarter was down 11.0% on a year-over-year basis. On average, research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were issued a dividend of $2.0369 per share. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date was Friday, May 9th. Sanofi's dividend payout ratio (DPR) is 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.